Sol-Gel Technologies Ltd. (SLGL)
NASDAQ: SLGL · IEX Real-Time Price · USD
0.919
+0.051 (5.90%)
At close: Jul 2, 2024, 3:10 PM
0.921
+0.002 (0.18%)
After-hours: Jul 2, 2024, 4:06 PM EDT
Sol-Gel Technologies Revenue
Sol-Gel Technologies had revenue of $1.72M in the twelve months ending March 31, 2024, down -58.84% year-over-year. Revenue in the quarter ending March 31, 2024 was $466.00K with 55.33% year-over-year growth. In the year 2023, Sol-Gel Technologies had annual revenue of $1.55M, a decrease of -59.98%.
Revenue (ttm)
$1.72M
Revenue Growth
-58.84%
P/S Ratio
14.89
Revenue / Employee
$47,778
Employees
36
Market Cap
25.61M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.55M | -2.33M | -59.98% |
Dec 31, 2022 | 3.88M | -27.39M | -87.58% |
Dec 31, 2021 | 31.27M | 22.50M | 256.54% |
Dec 31, 2020 | 8.77M | -14.13M | -61.71% |
Dec 31, 2019 | 22.90M | 22.78M | 17,655.04% |
Dec 31, 2018 | 129.00K | -45.00K | -25.86% |
Dec 31, 2017 | 174.00K | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Equillium | 37.89M |
Accelerate Diagnostics | 12.17M |
bioAffinity Technologies | 4.94M |
HCW Biologics | 1.16M |
Femasys | 1.05M |
SLGL News
- 6 weeks ago - Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel - GlobeNewsWire
- 3 months ago - Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream - GlobeNewsWire
- 3 months ago - Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments - GlobeNewsWire
- 7 months ago - Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study - GlobeNewsWire
- 7 months ago - Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 - GlobeNewsWire
- 8 months ago - Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 months ago - Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference - GlobeNewsWire